Keywords: texas, set, gain, icos, joint, venture, corp

Texas set to gain from ICOS joint venture

Article | 08 June 2000

ICOS Corp and Texas Biotechnology Corp are forming a 50:50 joint ventureto develop and commercialize endothelin-A receptor antagonists, to treat conditions ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Texas Biotechnology Corp

Go to company listing